Follicular Lymphoma Tumor
Follicular Lymphoma is an indolent B-cell neoplasm marked by characteristic genetic changes such as t(14;18). Biomarkers help guide targeted therapy approaches.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Follicular Lymphoma Tumor in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| EZH2 |
|
Defined at the solid tumor level and applicable to Follicular Lymphoma Tumor and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Follicular Lymphoma Tumor. Select a therapy to view the specific approval and eligible tests.
EZH2 (Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene)